BioTrends Announces the Continuation of a Syndicated Report Series: TreatmentTrends: CKD Stages 1-5ND Report Series Tracks Referral Patterns, Treatment Prevalence and Perception of New Products in Development Over Time
EXTON, Pa., March 13, 2013 /PRNewswire/ -- BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, announces the continuation of the report series entitled TreatmentTrends: Chronic Kidney Disease Stages 1-5 Non-Dialysis. BioTrends plans to field the third wave of this research similarly to the two waves conducted in 2012, with each wave consisting of findings from a quantitative survey with 250 physicians (100 nephrologists, 100 primary care physicians, and 50 endocrinologists). Below are some key findings from the second wave of this report series; these items and others will be tracked in the third wave of research to observe changes over time:
- The majority of physicians feel that patients are referred to nephrologists too late, nephrologists are significantly more likely than PCPs to feel this way
- According to nephrologists, the primary reason that PCPs refer CKD patients to nephrologists is based on a high creatinine level or rising creatinine levels
- For many medication classes, treatment tends to increase as CKD worsens - by Stage 5ND, approximately forty percent of patients are on phosphate binders, approximately forty percent are on oral active Vitamin D, and just over twenty percent are on erythropoiesis-stimulating agents
- Similar to the first wave of research, physicians tend to report moderate to high interest in Concert Pharmaceutical's CTP-499 and Mitsubishi Tanabe's AST-120
TreatmentTrends: Chronic Kidney Disease Stages 1-5 Non-Dialysis is a report series designed to track physician perception of the CKD-ND patient population, including referral patterns, patient load, current treatments, screening protocols, diagnosis patterns, frequency of comorbidities, unmet needs, and reaction to new products in development. TreatmentTrends: Chronic Kidney Disease Stages 1-5 Non-Dialysis, which is written by BioTrends Research Group nephrology experts, uses feedback provided directly from biotechnology and pharmaceutical organizations as well as nephrology thought leaders. Proprietary questions are solicited from key contacts at appropriate organizations. The third wave of this report will publish by July 3, 2013 with comments and proprietary questions for this wave due on March 22, 2013.
About BioTrends Research Group
BioTrends Research Group provides syndicated and custom primary market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharmaceutical markets. For information on BioTrends publications and research capabilities, please visit us at www.bio-trends.com. BioTrends is a Decision Resources Group company.
About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.
All company, brand, or product names contained in this document may be trademarks of their respective holders.
SOURCE BioTrends Research Group